The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.

Rec-Biotechnology (RecBio), the China-based vaccine developer backed by conglomerates China Resources and Legend Holdings, has raised HK$765m ($97.7m) in an initial public offering (IPO) on the Hong Kong Stock Exchange.

The company issued nearly 30.9 million shares priced at HK$24.80 each. Subsidiaries of pharmaceutical firm Yangtze River Pharmaceutical Group, investment manager Harvest Global Investments and venture capital firm Sequoia Capital China paid $53m to buy more than half of the issued shares as anchor investors.

Founded in 2012, RecBio focuses…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn